Human papillomavirus type 16 infection activates the host serine arginine protein kinase 1 (SRPK1) - splicing factor axis.
3T3 Cells
Alternative Splicing
/ genetics
Animals
HeLa Cells
Human papillomavirus 16
/ pathogenicity
Humans
Keratinocytes
/ physiology
Mice
Papillomavirus Infections
/ genetics
Phosphorylation
/ genetics
Protein Serine-Threonine Kinases
/ genetics
Serine-Arginine Splicing Factors
/ genetics
Up-Regulation
/ genetics
Viral Proteins
/ genetics
Virus Replication
/ genetics
cervical cancer
epithelial differentiation
human papillomavirus
infection
tumour progression
Journal
The Journal of general virology
ISSN: 1465-2099
Titre abrégé: J Gen Virol
Pays: England
ID NLM: 0077340
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
pubmed:
18
3
2020
medline:
27
10
2020
entrez:
18
3
2020
Statut:
ppublish
Résumé
The infectious life cycle of human papillomaviruses (HPVs) is tightly linked to keratinocyte differentiation. Evidence suggests a sophisticated interplay between host gene regulation and virus replication. Alternative splicing is an essential process for host and viral gene expression, and is generally upregulated by serine arginine-rich splicing factors (SRSFs). SRSF activity can be positively or negatively controlled by cycles of phosphorylation/dephosphorylation. Here we show that HPV16 infection leads to accumulation of the paradigm SRSF protein, SRSF1, in the cytoplasm in a keratinocyte differentiation-specific manner. Moreover, HPV16 infection leads to increased levels of cytoplasmic and nuclear phosphorylated SRSF1. SR protein kinase 1 (SRPK1) phosphorylates SRSF1. Similar to HPV upregulation of SRSF1, we demonstrate HPV upregulation of SRPK1 via the viral E2 protein. SRPK1 depletion or drug inhibition of SRPK1 kinase activity resulted in reduced levels of SRSF1, suggesting that phosphorylation stabilizes the protein in differentiated HPV-infected keratinocytes. Together, these data indicate HPV infection stimulates the SRPK1-SRSF axis in keratinocytes.
Identifiants
pubmed: 32182205
doi: 10.1099/jgv.0.001402
pmc: PMC7414453
doi:
Substances chimiques
Viral Proteins
0
Serine-Arginine Splicing Factors
170974-22-8
SRPK1 protein, human
EC 2.7.1.-
Protein Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
523-532Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12014/9
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12014
Pays : United Kingdom
Références
Biochem J. 2009 Jan 1;417(1):15-27
pubmed: 19061484
RNA. 2014 Apr;20(4):474-82
pubmed: 24550521
Nat Rev Microbiol. 2013 Apr;11(4):239-51
pubmed: 23474685
Int J Biol Sci. 2010 Dec 15;6(7):806-26
pubmed: 21179588
J Biol Chem. 2000 Mar 17;275(11):7950-7
pubmed: 10713112
Virology. 2010 Jun 5;401(2):155-64
pubmed: 20227104
FEBS J. 2011 Feb;278(4):570-86
pubmed: 21205200
RNA. 1998 Apr;4(4):430-44
pubmed: 9630249
PLoS Pathog. 2011 Nov;7(11):e1002388
pubmed: 22114561
J Virol. 2017 Nov 30;91(24):
pubmed: 29021401
Clin Sci (Lond). 2017 Aug 10;131(17):2201-2221
pubmed: 28798073
J Virol. 1995 May;69(5):2989-97
pubmed: 7707525
J Virol. 2007 Jun;81(11):5437-48
pubmed: 17360743
J Virol. 2004 Oct;78(19):10598-605
pubmed: 15367627
Mol Cell. 2016 Jul 21;63(2):218-228
pubmed: 27397683
Virology. 2014 Nov;468-470:10-18
pubmed: 25129434
Adv Virus Res. 2009;74:1-40
pubmed: 19698894
J Virol. 2019 Jun 14;93(13):
pubmed: 30996086
J Virol. 2014 Nov;88(21):12599-611
pubmed: 25142587
Cancer Cell. 2011 Dec 13;20(6):768-80
pubmed: 22172722
J Virol. 2002 Aug;76(16):8124-37
pubmed: 12134018
Biomolecules. 2015 May 05;5(2):758-74
pubmed: 25950509
Proteomics. 2015 Jun;15(12):2038-50
pubmed: 25758368
Cancer Res. 2010 Jul 1;70(13):5316-25
pubmed: 20530671
Virus Res. 2017 Mar 2;231:83-95
pubmed: 27867028
EMBO J. 2003 Apr 1;22(7):1608-19
pubmed: 12660167
Viruses. 2015 Jul 16;7(7):3863-90
pubmed: 26193301
J Virol. 2016 Sep 12;90(19):8384-8
pubmed: 27412596
Virology. 2009 Mar 30;386(1):32-43
pubmed: 19187948
Virology. 2013 Oct;445(1-2):57-79
pubmed: 23849793
Mol Cell. 2012 Aug 10;47(3):422-33
pubmed: 22727668
Mol Cancer Res. 2014 Sep;12(9):1195-204
pubmed: 24807918
J Invest Dermatol. 2000 Mar;114(3):444-55
pubmed: 10692102
J Virol. 2009 Jan;83(1):167-80
pubmed: 18945760
Mol Biol Rep. 2019 Feb;46(1):1487-1497
pubmed: 30535769
Mol Cell Biol. 2002 Oct;22(19):6871-82
pubmed: 12215544
Mol Cell. 2008 Apr 25;30(2):179-89
pubmed: 18439897
Open Virol J. 2012;6:173-89
pubmed: 23341853
Chromosoma. 2013 Jun;122(3):191-207
pubmed: 23525660
Oncogene. 2005 Nov 24;24(53):7830-8
pubmed: 16044149
Future Microbiol. 2010 Oct;5(10):1493-506
pubmed: 21073310
J Virol. 2012 Jun;86(11):6358-64
pubmed: 22457518
PLoS Pathog. 2012;8(6):e1002761
pubmed: 22761572
J Biol Chem. 2003 Dec 26;278(52):52223-30
pubmed: 14559922
Cancer Res. 2006 Jun 1;66(11):5555-9
pubmed: 16740689
Virology. 2009 Feb 20;384(2):260-5
pubmed: 19135222
J Virol. 2009 Jan;83(1):357-67
pubmed: 18945764
J Virol. 2016 Apr 29;90(10):5047-58
pubmed: 26962216
Innate Immun. 2013 Oct;19(5):516-30
pubmed: 23405030
Int J Cancer. 1989 Apr 15;43(4):672-6
pubmed: 2467886
Wiley Interdiscip Rev RNA. 2015 Jan-Feb;6(1):93-110
pubmed: 25155147
Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11329-33
pubmed: 16840555
Genes Dev. 2004 Apr 1;18(7):755-68
pubmed: 15082528
J Pathol. 2009 Nov;219(3):383-91
pubmed: 19718710
J Virol. 2015 May;89(10):5276-87
pubmed: 25717103
Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15042-7
pubmed: 16210245
J Cell Biol. 2000 Aug 21;150(4):707-18
pubmed: 10952997
PLoS One. 2011 Feb 15;6(2):e17202
pubmed: 21358805